Double antiviral attack: could two flu drugs beat one for vulnerable patients?

NCT ID NCT04712539

First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether combining two antiviral drugs, baloxavir and oseltamivir, works better than oseltamivir alone for severe flu in people with weakened immune systems (such as blood cancer patients or stem cell transplant recipients). The study will measure how quickly the virus clears and whether the combination reduces hospital stays or complications. 60 participants are being recruited at MD Anderson Cancer Center.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Baloxavir marboxil and oseltamivir
What this could lead to
If it works, this combination could offer a more effective treatment for severe flu in people with weakened immune systems, reducing hospital stays and complications.
What could go wrong
This is a small, early-phase trial (60 participants) in a very specific group (cancer or transplant patients). The combination may not work better than oseltamivir alone, and there is a risk of side effects or drug resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.